Clinical trial
A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT05935748 is registered in ClinicalTrials.gov with NiKang Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Lead sponsor
- NiKang Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 28, 2023
- Completion date
- September 4, 2025
- Enrollment
- 18 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, advanced renal cell carcinoma, carcinoma, carcinoma, renal cell, ccrcc, clear cell renal cell carcinoma, kidney cancer, kidney diseases, kidney neoplasms, metastatic renal cell carcinoma, neoplasm by histology, neoplasms, neoplasms by site, neoplasms, glandular and epithelial, recurrent renal cell carcinoma, refractory renal cell carcinoma, renal cancer, renal neoplasms, urogenital neoplasms, urologic diseases, urologic neoplasms